Clinical data | |
---|---|
Drug class | Reverse transcriptase inhibitor |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C16H23N4O6 |
Molar mass | 367.382 g·mol−1 |
3D model (JSmol) | |
| |
|
KP-161 is an experimental antiviral drug being studied for the treatment of HIV/AIDS.[1] It belongs to the class of nucleoside reverse transcriptase inhibitors.[2]
KP-1461 is a prodrug of the active antiviral agent KP-1212.[3]